Clinical trials: Aids, Cdc Group I
Aids, Cdc Group I
HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Treatment: Immunization with peptide-mix and adjuvant. The vaccine should induce cellular immunity against HIV-1. Target group: Untreated healthy individuals with chronic HIV-1 infection.
- Trial name
- HIV-BIS (NCT01141205)
- Testing
- AFO-18, Saline
- Where
- 2 sites in Guinea-Bissau
- Volunteers
- 18 people
- Sponsor
- Statens Serum Institut